BD Appoints Two Business Unit Presidents

- Puneet Sarin Named President of Medication Management Solutions
- Steve Conly Named President of Biosciences

FRANKLIN LAKES, N.J. (Sept. 8, 2022) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Puneet Sarin has been named president of BD Medication Management Solutions, and Steve Conly has been named president of BD Biosciences, both effective Oct. 3.

In these roles, Sarin and Conly will be responsible for driving global strategic, operational and commercial performance of their respective business units. Sarin will report to Mike Garrison, executive vice president (EVP) and president of the Medical segment, and Conly will report to Dave Hickey, EVP and president of the Life Sciences segment.

"Puneet has proven strategic and operational performance as a business unit president at BD and is well positioned to lead MMS into the future," Garrison said. "Puneet has reinvigorated our Biosciences business through several new innovations and customer experience improvements that have solidified BD's leadership in flow cytometry and immunology. I look forward to transitioning the MMS president role to Puneet as we continue to focus on the fundamentals, further our commitment culture and drive innovation for advancing health care worldwide."

Hickey added, "Steve is a known expert and leader in the life sciences industry and has spent 12 years at BD leading multiple platforms across both Integrated Diagnostic Solutions and Biosciences, most recently as the P&L leader for all of our research and clinical solutions platforms across BDB. Promoting Steve to president at BDB was part of our robust, planned succession process, and I am fully confident that he will continue to drive innovation and growth at BDB."

Puneet Sarin, president of Medication Management Solutions

Sarin, 48, replaces Mike Garrison who was recently promoted to EVP and president of the BD Medical segment. Sarin joined BD in 2019 as president of BDB and has reinvigorated innovation and simplified the customer experience. Earlier this year, BDB unveiled a first-to-world cell sorter that combines advanced spectral flow cytometry with sort-capable image analysis, which has solidified BD's technology leadership in flow cytometry. He also simplified the customer experience through a reimagined digital marketplace designed to provide an enhanced online purchasing experience for users and their procurement teams. Prior to BD, Sarin held a variety of P&L leadership roles at Danaher and GE Healthcare. Puneet earned his Bachelor of Science in Mechanical Engineering from Milwaukee School of Engineering and his Master of Business Administration from Emory University.

Steve Conly, president of Biosciences

Conly, 39, replaces Sarin who has been named president of MMS. Conly joined BD in 2010 as a marketing manager for Laboratory Automation in the Integrated Diagnostic Solutions business. He was promoted to platform leader for Laboratory Automation in 2012 and was then appointed to the platform leadership position for Microbiology in 2015. Conly was promoted to VP and GM for Microbiology in 2016. Conly moved to the Biosciences business unit in 2020 as VP and GM for Research Solutions. He added Clinical Solutions to his responsibilities in 2021. Conly earned his Bachelor of Arts and Science in Biomedical Sciences and Economics from McGill University in Canada.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

Contacts:

Media:

Troy Kirkpatrick VP, Public Relations 858.617.2361 troy.kirkpatrick@bd.com Investors:

Francesca DeMartino SVP, Head of Investor Relations 201.847.5743 francesca.demartino@bd.com

Additional assets available online: Photos (2)

https://news.bd.com/2022-09-08-BD-Appoints-Two-Business-Unit-Presidents